James E Thompson MD M.S. (He/Him)

PubMed

• Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.
  Jeffrey Baron, Daniel Appiah, Mark G Faber, Han Yu, Tara Cronin
  Leukemia & Lymphoma. 2025-05-01
• Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy.
  Sawyer Bawek, Matthew Burwinkel, Prutha Patel, Katy Wang, Kristopher Attwood
  Leukemia Research. 2025-03-01
• 29 citations
  Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
  Naval G Daver, Pau Montesinos, Daniel J DeAngelo, Eunice S Wang, Nikolaos Papadantonakis
  The Lancet. Oncology. 2024-03-01

Abstracts/Posters

• Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study
  James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid...
  James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone
  James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Quantification of Humoral Immune Response to Influenza Vaccination in MDS
  James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
  James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A ...
  James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all